atenolol has been researched along with caffeine in 53 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (5.66) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 17 (32.08) | 29.6817 |
2010's | 21 (39.62) | 24.3611 |
2020's | 12 (22.64) | 2.80 |
Authors | Studies |
---|---|
Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
Topliss, JG; Yoshida, F | 1 |
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
Carrupt, PA; Martel, S; Ottaviani, G | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Conradi, R; Lee, PH; Shanmugasundaram, V | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Avdeef, A; Tam, KY | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Brea, J; Cadavid, MI; Campillo, NE; Ceballos, P; Gil, C; Loza, MI; Martínez, A; Moro, MA; Pérez, C; Pérez, DI; Perez-Castillo, A; Redondo, M; Val, C; Zarruk, JG | 1 |
Andrisano, V; Bolognesi, ML; Carloni, P; Cavalli, A; Chiriano, G; De Simone, A; Legname, G; Mancini, F; Martinez, A; Perez, DI; Roberti, M | 1 |
Alonso-Gil, S; Campillo, NE; Castro, A; Encinas, A; Gil, C; Martinez, A; Morales-Garcia, JA; Palomo, V; Perez, C; Perez, DI; Perez-Castillo, A; Soteras, I | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Alonso-Gil, S; Chavarría, C; Gil, C; Morales Garcia, JA; Pérez, C; Perez, DI; Pérez-Castillo, A; Porcal, W; Souza, JM | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bello, ML; Gil, C; Kraemer, BC; Lecourtois, M; Liachko, NF; Martinez, A; Miguel, L; Perez, C; Perez, DI; Redondo, M; Salado, IG | 1 |
Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Campillo, NE; Geiger, L; Gil, C; González, S; Li, L; Martinez, A; Morales, AV; Perez, DI; Salado, IG; Sebastián-Pérez, V; Zaldivar-Diez, J | 1 |
Campillo, NE; Cañada, FJ; Canales, A; Carvalho, I; Chierrito, TPC; Martinez, A; Martínez-Gonzalez, L; Pedersoli-Mantoani, S; Perez, C; Pérez, DI; Roca, C; Sebastian-Pérez, V | 1 |
Cheng, M; Guo, J; Jiang, N; Li, Q; Liang, N; Liu, J; Nong, X; Pang, C; Qin, Y; Tang, C; Tang, W; Xie, SS; Zhang, Z | 1 |
Balliano, TL; Barbosa, G; Carvalho, VF; da Silva, BA; de Souza, ET; Lima, LM; Martins, IRR; Martins, MA; Medeiros, MM; Moraes Junior, MO; Nunes, IKDC; Silva, PMR; Silva, SWD | 1 |
Cheng, M; Fang, Y; Guo, J; Jin, Y; Liu, J; Wan, Y; Wang, R; Xie, SS; Zhang, Z; Zhou, W | 1 |
Abdel-Maksoud, MS; Ali, EMH; Ammar, UM; Choi, HS; El-Gamal, MI; Gamal El-Din, MM; Han, DK; Jeon, HR; Kim, G; Kwon, D; Kwon, YJ; Lee, BS; Lee, JK; Lee, KH; Lee, KT; Mersal, KI; Oh, CH; Yoo, KH | 1 |
Chen, H; Ding, H; Gao, Y; Jiang, X; Liu, W; Liu, X; Tian, L; Xu, Z; Zhao, Q | 1 |
Chaikuad, A; de Lago, E; Gil, C; Gomez-Almeria, M; Gonzalo-Consuegra, C; Knapp, S; Lietha, D; Martín-Requero, A; Martinez, A; Martínez-González, L; Monti, B; Nozal, V; Palomo, V; Pérez-Cuevas, E; Petralla, S; Ramírez, D; Santana, P | 1 |
Cariello, L; Nelson, L | 1 |
Arita, M; Nakagawa, A; Shimada, T; Shirabe, J | 1 |
Bianchi, M; Sora, S | 1 |
Asakawa, N; Ishihama, Y; Murata, K; Yamamoto, E | 1 |
Adriaensen, J; Augustijns, P; Brewster, ME; Mackie, C; Melis, A; Mensch, J; Noppe, M | 1 |
Carriquiriborde, P; Elorriaga, Y; Marino, DJ; Ronco, AE | 1 |
Tang, X; Thiele-Bruhn, S; Zhang, W | 1 |
Correia, AT; de Oliveira, TMN; Guimarães, LL; Pisetta, AM; Roveri, V | 1 |
Correia, AT; Guimarães, LL; Roveri, V; Toma, W | 1 |
Thiele-Bruhn, S; Zhang, W | 1 |
Corvini, PF; Demaria, F; Kolvenbach, BA; Suleiman, M; Zimmardi, C | 1 |
Ben, W; Chen, Y; Liu, Z; Ma, Y; Su, D; Wang, Y; Wei, Y | 1 |
1 review(s) available for atenolol and caffeine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
52 other study(ies) available for atenolol and caffeine
Article | Year |
---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
Topics: Humans; Membranes, Artificial; Models, Biological; Models, Molecular; Octanols; Permeability; Pharmaceutical Preparations; Skin Absorption; Water | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.
Topics: 1-Methyl-3-isobutylxanthine; Cell Line; Cell Membrane Permeability; Humans; Models, Biological; Quantitative Structure-Activity Relationship; Skin Absorption | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Enzyme Inhibitors; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Permeability; Quinazolines; Stroke | 2012 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Survival; Chickens; Humans; Imidazoles; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Models, Molecular; Neurons; Small Molecule Libraries; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship | 2012 |
5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Blood-Brain Barrier; Cell Death; Cell Differentiation; Cell Membrane Permeability; Cells, Cultured; Glycogen Synthase Kinase 3; Hippocampus; Humans; Imines; In Vitro Techniques; Lipopolysaccharides; Membranes, Artificial; Microglia; Models, Molecular; Neural Stem Cells; Neurogenesis; Neurons; Neuroprotective Agents; Nitrites; Protein Binding; Rats; Structure-Activity Relationship; Substrate Specificity; Swine; Thiadiazoles | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Microwave-assisted synthesis of hydroxyphenyl nitrones with protective action against oxidative stress.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood-Brain Barrier; Cell Survival; Dose-Response Relationship, Drug; Humans; Microwaves; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Nitrogen Oxides; Oxidative Stress; Oxidopamine; Peroxynitrous Acid; Structure-Activity Relationship; Tyrosine | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Benzothiazoles; Blood-Brain Barrier; Casein Kinase I; Cell Membrane Permeability; Cells, Cultured; DNA-Binding Proteins; Drosophila; Drug Design; Drug Discovery; HEK293 Cells; Heterocyclic Compounds; High-Throughput Screening Assays; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Neurons; Neurotoxicity Syndromes; Phosphorylation; Protein Kinase Inhibitors; Substrate Specificity | 2014 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain Barrier; Cholinesterase Inhibitors; Humans; In Vitro Techniques; Molecular Structure | 2015 |
Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
Topics: Animals; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Indoles; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Neural Stem Cells; Neuroprotective Agents; Protein Kinase Inhibitors; Structure-Activity Relationship | 2017 |
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Indoles; Molecular Structure; Piperidines; Structure-Activity Relationship | 2018 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose-Response Relationship, Drug; Drug Design; Humans; Indans; Male; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2020 |
Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
Topics: Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Drug Design; Enzyme Inhibitors; Humans; Hydrazones; Hypersensitivity; Lung; Male; Mice | 2020 |
Design, synthesis, and biological evaluation of novel xanthone-alkylbenzylamine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzothiazoles; Benzylamines; Biphenyl Compounds; Butyrylcholinesterase; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Male; Mice; Mice, Inbred Strains; Molecular Structure; Neuroprotective Agents; Picrates; Rats; Structure-Activity Relationship; Sulfonic Acids; Xanthones | 2021 |
Discovery of New Imidazo[2,1-
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Drug Stability; Half-Life; Humans; Imidazoles; Melanoma; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Docking Simulation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Structure-Activity Relationship; Sulfonamides; Thiazoles; Transplantation, Heterologous | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyrk Kinases; Glycogen Synthase Kinase 3 beta; Harmine; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2021 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; Inflammation; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spinal Cord; Tissue Distribution | 2022 |
Adrenergic stimulation of sea urchin sperm cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Caffeine; Calcium; Heterocyclic Compounds; Male; Sea Urchins; Sperm Motility; Spermatozoa; Verapamil | 1989 |
Effects of mechanical stretch on the membrane potential of guinea pig ventricular muscles.
Topics: Action Potentials; Animals; Atenolol; Atropine; Caffeine; Electric Stimulation; Female; Gallopamil; Guinea Pigs; In Vitro Techniques; Male; Membrane Potentials; Microelectrodes; Muscle Contraction; Muscles; Papillary Muscles; Ryanodine; Time Factors | 1988 |
Propranolol, atenolol, and trifluoperazine reduce the spontaneous occurrence of meiotic diploid products in Saccharomyces cerevisiae.
Topics: Atenolol; Caffeine; Diploidy; Propanolamines; Propranolol; Saccharomyces cerevisiae; Spores, Fungal; Trifluoperazine | 1982 |
Methylcellulose-immobilized reversed-phase precolumn for direct analysis of drugs in plasma by HPLC.
Topics: Animals; Atenolol; Caffeine; Chromatography, Gel; Chromatography, High Pressure Liquid; Humans; Ketoprofen; Male; Methylcellulose; Pharmaceutical Preparations; Propranolol; Proteins; Rats; Silicon Dioxide; Time Factors | 2001 |
Novel generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early Drug Discovery.
Topics: Ampicillin; Atenolol; Caffeine; Carbamazepine; Chromatography, High Pressure Liquid; Griseofulvin; Permeability; Pharmaceutical Preparations; Propranolol; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
Human pharmaceuticals in wastewaters from urbanized areas of Argentina.
Topics: Argentina; Atenolol; Caffeine; Carbamazepine; Chromatography, High Pressure Liquid; Cities; Diclofenac; Environmental Monitoring; Humans; Ibuprofen; Mass Spectrometry; Pharmaceutical Preparations; Wastewater; Water Pollutants, Chemical | 2013 |
Interaction of pig manure-derived dissolved organic matter with soil affects sorption of sulfadiazine, caffeine and atenolol pharmaceuticals.
Topics: Adsorption; Animals; Atenolol; Caffeine; Ecosystem; Manure; Pharmaceutical Preparations; Soil; Soil Pollutants; Sulfadiazine; Swine | 2021 |
First report on the occurrence of pharmaceuticals and cocaine in the coastal waters of Santa Catarina, Brazil, and its related ecological risk assessment.
Topics: Acetaminophen; Atenolol; Brazil; Caffeine; Carbamazepine; Chromatography, Liquid; Cocaine; Cosmetics; Diclofenac; Ecosystem; Environmental Monitoring; Humans; Losartan; Orphenadrine; Pharmaceutical Preparations; Risk Assessment; Sewage; Solid Waste; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical | 2022 |
Occurrence, ecological risk assessment and prioritization of pharmaceuticals and abuse drugs in estuarine waters along the São Paulo coast, Brazil.
Topics: Acetaminophen; Atenolol; Brazil; Caffeine; Carbamazepine; Chromatography, Liquid; Cocaine; Diclofenac; Ecosystem; Environmental Monitoring; Furosemide; Illicit Drugs; Losartan; Orphenadrine; Pharmaceutical Preparations; Risk Assessment; Rivers; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2022 |
Influence of Manure as a Complex Mixture on Soil Sorption of Pharmaceuticals-Studies with Selected Chemical Components of Manure.
Topics: Adsorption; Atenolol; Caffeine; Manure; Pharmaceutical Preparations; Phenols; Soil; Soil Pollutants; Sulfadiazine | 2023 |
Analyzing microbial communities and their biodegradation of multiple pharmaceuticals in membrane bioreactors.
Topics: Acetaminophen; Atenolol; Biodegradation, Environmental; Bioreactors; Caffeine; Environmental Pollutants; Ibuprofen; Microbiota; Pharmaceutical Preparations; RNA, Ribosomal, 16S; Water Pollutants, Chemical | 2023 |
Distribution, ecological risks and priority of pharmaceuticals in the coastal water of Qinhuangdao, China.
Topics: Atenolol; Caffeine; China; Environmental Monitoring; Pharmaceutical Preparations; Risk Assessment; Water; Water Pollutants, Chemical | 2024 |